Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
41556616 (PubMed )
Supplement: PRO-35-e70422-s002.xlsx › Table_S1
Establishment and validation of a phenotype-driven predictive model for the diagnostic efficacy of trio-based whole exome sequencing (trio-WES) in children with genetic neurodevelopmental disorders (g-NDDs).
Wu R et al.
Frontiers in Neurology, 2025
41170324 (PubMed )
Supplement: Data_Sheet_5.XLS › NDD-NPDs
Tumor-derived ARHGAP35 mutations enhance the Gα13-Rho signaling axis in human endometrial cancer.
Yagi H et al.
Cancer Gene Therapy, 2023
Identification of an inhibitory domain in GTPase-activating protein p190RhoGAP responsible for masking its functional GAP domain.
Héraud C et al.
The Journal of Biological Chemistry, 2023
Mutational drivers of cancer cell migration and invasion.
Novikov NM et al.
British Journal of Cancer, 2021
p190A inactivating mutations cause aberrant RhoA activation and promote malignant transformation via the Hippo-YAP pathway in endometrial cancer.
Wen X et al.
Signal Transduction and Targeted Therapy, 2020
p190RhoGAPs, the ARHGAP35- and ARHGAP5-Encoded Proteins, in Health and Disease.
Héraud C et al.
Cells, 2019
Cancer-associated mutations in the protrusion-targeting region of p190RhoGAP impact tumor cell migration.
Binamé F et al.
The Journal of Cell Biology, 2016
Select a paper to view details